Parallel Health World News Logo

Parallel Health World

cropper
  • Home
  • Categories
    • EcoHealth Trends
    • Healing Naturally
    • Age-Defying Diets
    • Supplement Savvy
    • Mind-Body Synergy
    • Finance and Health
    • Biolimitless
    • Tech Hacks
    • Health & Medicine
    • Political
    • BioBuzz
    • Holistic Rehabilitation Techniques
    • Practitioner Insights
    • AI In Healthcare
  • Featured Business Profiles
December 31.2025
1 Minute Read

Discover the Hidden Power of Rare Disease Research Today

Did you know fewer than 5% of rare diseases have approved treatments, even though over 300 million people live with a rare disease worldwide? These statistics reveal an urgent, often overlooked health crisis—but they also highlight a powerful opportunity for innovation and hope

Unveiling the Impact: Startling Facts About Rare Disease Research

  • Rare diseases affect over 300 million people worldwide.
  • Less than 5% of rare diseases have approved treatments.
"For every rare disease patient, innovative research is hope." – Leading Clinical Research Expert

Diverse group at rare disease awareness event supporting rare disease research

What You'll Learn About Rare Disease Research

  • Why rare disease research is critical to medical advancement
  • The landscape of rare diseases and the global research network
  • How clinical trials and patient advocacy transform lives
  • Ways to get involved and make a difference

Why Rare Disease Research Matters: Advancements, Hope, and the Future

Rare Diseases: The Unseen Health Crisis

  • Definition and prevalence of rare diseases
  • Challenges faced by rare disease patients and families

Rare disease research shines a spotlight on health conditions impacting fewer than 200,000 people per disease in the United States alone. These rare diseases—ranging from genetic disorders to resistant KD and beyond—collectively touch the lives of over 300 million people worldwide. Despite their prevalence, families living with rare diseases often feel isolated due to a lack of information, limited support, and few available treatments. The disease community constantly depends on the few clinical care specialists and information specialists available, yet many conditions—such as progeria or Batten disease—have no current cures. Rare disease patients face lengthy diagnostic journeys, high medical costs, and uncertainty, making research vital not only for finding therapies but also for hope itself.

The challenges for rare disease patients and their families are immense. Treatment options for most rare diseases are scarce, with less than 5% of these diseases currently having an FDA-approved therapy. The absence of adequate clinical trials and specialized infusion center support only adds to the burden for patients and clinical research teams alike. This gap is why patient advocacy and a robust research network are so crucial, as they work tirelessly to raise awareness and develop new solutions, ensuring that the voices of people living with rare disease are finally heard.

Family supporting a young woman affected by a rare disease; rare disease patient community and family support

Building a Rare Disease Research Network: Collaboration for Breakthroughs

The Role of Clinical Research and Clinical Trials

  • How clinical trials advance new treatments for rare diseases
  • Leading institutions, like the California Center, championing research

Clinical research and clinical trials are the engines that power innovation in rare disease research. Through rigorous studies, clinical research experts explore new drugs, gene therapies, and novel approaches, bringing hope to people living with rare disease. Every clinical trial is a critical step forward, offering rare disease patients opportunities to participate and shape the future of medical care. Institutions such as the California Center stand at the forefront, not only leading clinical trials but also serving as information specialists for disease patients and their families. Their commitment bridges the gap between scientific discovery and patient support, fostering international collaboration and sharing summaries of recent breakthroughs.

Networking is central to rare disease research progress. A research network spanning continents allows clinicians, scientists, and patient advocacy groups to pool data, share best practices, and optimize the development of targeted therapies. Expert clinicians and information specialists work together to respond to your inquiry, ensuring that patients from all backgrounds—whether seeking clinical trials or daily clinical care—receive guidance, support, and the latest clinical trial opportunities. By connecting rare disease communities globally, these networks accelerate the translation of research findings into real-world changes, ultimately improving quality of life for millions.

Effective communication is also essential for research teams and advocacy groups to share updates and coordinate efforts. Leveraging innovative tools such as video email platforms can help streamline outreach, making it easier to connect with patients, clinicians, and supporters across the globe.

Clinical research team advancing rare disease research and discussing data in a high-tech laboratory

Patient Advocacy: Giving Rare Disease Patients a Voice

  • The importance of empowering rare disease patient communities
"Patient advocacy accelerates rare disease research outcomes." – Patient Advocate

Patient advocacy is one of the most influential forces in the field of rare disease research. Dedicated advocacy groups ensure that rare disease patients are not just subjects of research but active participants shaping priorities and policies. By raising awareness, sharing stories, and mobilizing resources, patient advocacy creates a unified voice for the rare disease patient community—connecting families with expert clinicians, clinical research teams, and opportunities to participate in pivotal clinical trials. These efforts pave the way for additional support services, such as information specialists and outreach through disease community organizations, making information about clinical trials and new treatments more accessible than ever.

Advocacy also drives legislative change and helps secure funding for rare disease research initiatives. Organizations work tirelessly to promote events like Disease Day, encourage donations, and enlist volunteers to support their cause. By empowering people living with rare disease, advocacy networks ensure patient priorities remain at the heart of research, turning hope into action—and research outcomes into meaningful change.

How to Support Rare Disease Research: Getting Involved

  • Join awareness events on Disease Day
  • Participate in clinical research or clinical trials
  • Donate to research networks or patient advocacy groups
  • Share rare disease stories to raise visibility

You can play a key role in advancing rare disease research, no matter your background. Participation starts with raising awareness—attend events like Disease Day, where the rare disease community comes together to spotlight urgent needs and celebrate progress. Learn how to enroll in clinical trials or support research initiatives at leading centers such as the California Center. Clinical trials often provide opportunities for both patients and healthy volunteers, paving the way for medical breakthroughs that benefit the entire disease community.

Financial support is another lifeline for research networks and patient advocacy groups. Even small donations empower organizations to fund studies, train clinical research specialists, and offer information services to people living with rare disease. By sharing rare disease stories online, through social media, or within your community, you help raise the visibility of these urgent health issues and encourage others to get involved. Every action you take brings hope closer to millions around the world searching for answers and cures.

Volunteers supporting rare disease research at Disease Day; raising awareness and collecting donations

People Also Ask About Rare Disease Research

What is rare disease research?

  • Rare disease research seeks to understand and develop treatments for diseases affecting fewer than 200,000 people, driving innovation in medicine.

Rare disease research is a specialized field focused on uncovering the underlying causes, developing diagnostics, and creating therapies for rare diseases that impact smaller but significant segments of the global population. By advancing clinical research and supporting robust research networks, scientists and clinicians strive to address the gaps that traditional medical research leaves behind. These efforts not only help rare disease patients but often lead to discoveries benefiting a broader array of health conditions. Participating in a clinical trial or engaging with patient advocacy can fuel this essential work.

Can I get paid for having a rare disease?

  • Some clinical trials and research studies offer compensation to rare disease patients for participation, depending on the study and location.

Yes, compensation is sometimes available for individuals participating in clinical trials and clinical research focused on rare diseases. The amount and availability of compensation can vary widely, depending on the organization, the particular trial, and local regulations. Clinical trials conducted at institutions like the California Center often provide stipends or cover travel expenses for rare disease patient volunteers. If you are interested in participating, consult clinical care providers or research network resources for opportunities to participate and guidance.

What is the rarest disease in the world?

  • Conditions like ribose-5-phosphate isomerase deficiency are among the rarest, with only a handful of documented cases globally.

Ribose-5-phosphate isomerase deficiency is considered one of the rarest diseases, with only a few cases recorded worldwide. Research into such ultra-rare diseases is particularly challenging due to the scarcity of patients, limited clinical data, and obstacles in designing clinical trials. Nonetheless, these cases underscore the urgent need for international research networks and disease day awareness campaigns—ensuring every rare disease patient, no matter how small the community, receives attention and hope for a better future.

What rare disease has no cure?

  • Many rare diseases, such as progeria or Batten disease, currently have no cures, underscoring the need for more clinical research.

Despite advances in medicine, many rare diseases remain without any approved cures. Progeria, Batten disease, and hundreds of other rare diseases still challenge researchers, making it critical to fund clinical trials and build thriving research networks. Patient advocacy plays an indispensable role by highlighting these needs, connecting families with information specialists, and driving support for ongoing research. Involvement in disease day events, clinical trial participation, or donations can ignite the progress needed to find new treatments.

FAQs About Rare Disease Research

  • What is the definition of a rare disease?

A rare disease in the United States is defined as a condition affecting fewer than 200,000 people at any given time. These diseases can be genetic, acquired, or even resistant KD (Kawasaki disease). Each rare disease is distinct, requiring targeted clinical research for diagnosis and treatment.

  • How can individuals participate in rare disease clinical trials?

Individuals interested in clinical trial participation can start by consulting with clinical care providers, contacting information specialists at leading centers, or registering with clinical research networks. Many organizations offer opportunities to participate through online platforms, disease day events, and local advocacy groups.

  • Which organizations fund rare disease research initiatives?

Multiple organizations support rare disease research, including government agencies like the National Institutes of Health (NIH), disease-specific advocacy foundations, the California Center, pharmaceutical companies, and global research networks. These funders underpin the scientific progress that fuels hope for millions of rare disease patients.

Keynote speaker presenting breakthroughs in rare disease research at a global conference

Key Takeaways: The Vital Role of Rare Disease Research

  • Rare disease research fuels medical breakthroughs for all.
  • Patient advocacy and research networks are essential for progress.
  • Your involvement can lead to hope and change for millions.

Explore the Rare Disease Research Network Today

  • Ready to power progress? Join our rare disease research campaign and make an impact—download our exclusive resource or sign up for updates now.

Inspiring global research network—scientists and advocates collaborating across the world

Comparison of Rare Disease Research Initiatives: Focus Areas, Funders, and Participation Opportunities

Initiative / Network Key Focus Areas Main Funders Participation Opportunities
California Center for Rare Diseases Genetic Rare Diseases, Clinical Trials, Patient Advocacy NIH, Private Foundations Patient enrollment, Disease Day events, Research collaborations
Global Rare Disease Research Network International Collaboration, Data Sharing, New Drug Development Government Grants, Industry Partners Clinical trial participation, Virtual seminars, Advocacy volunteer work
Rare Disease Patient Advocacy Foundation Awareness, Community Education, Research Funding Donor Support, Corporate Sponsorships Donations, Story sharing, Peer mentoring programs
NIH Office of Rare Diseases Policy, Funding, Research Coordination Federal Government Research proposals, Training, Public consultations

Conclusion

Your voice and actions make a difference—explore rare disease research, join a clinical trial, share a story, or donate today to help pave the path to hope for millions.

As you continue your journey in supporting rare disease research, consider how innovative communication tools can amplify your impact—whether you're sharing patient stories, organizing virtual events, or connecting with global advocates. Harnessing the power of video email technology can help you reach wider audiences and foster stronger collaborations within the rare disease community. By embracing new ways to engage and inform, you not only raise awareness but also inspire action and drive meaningful change. Explore how digital solutions can elevate your advocacy and help bring hope to those who need it most.

Sources

  • NIH Genetic and Rare Diseases Information Center – https://rarediseases.info.nih.gov
  • Rare Disease Day – https://www.rarediseaseday.org
  • EURORDIS – https://www.eurordis.org
  • Global Genes – https://globalgenes.org
  • ClinicalTrials.gov – https://clinicaltrials.gov

Rare disease research is a critical field that addresses the needs of over 30 million Americans affected by various rare conditions. The National Institutes of Health (NIH) emphasizes the importance of this research, noting that while individual rare diseases are uncommon, collectively they have a significant public health impact. (nih.gov)

The National Organization for Rare Disorders (NORD) is a nonprofit organization dedicated to supporting individuals with rare diseases through advocacy, research funding, education, and networking among service providers. (rarediseases.org)

Additionally, the Rare Diseases Clinical Research Network (RDCRN), funded by the NIH, facilitates collaboration among scientists, clinicians, and patient advocacy groups to study over 280 rare diseases. This network aims to advance medical research by supporting clinical studies and promoting data sharing. (ncats.nih.gov)

For those seeking to participate in clinical trials or connect with research initiatives, Know Rare offers resources to help navigate the complexities of rare disease research. Their platform provides access to support, tools, and knowledge from top leaders and researchers in the field. (knowrare.com)

Engaging with these organizations can provide valuable insights and opportunities to contribute to the advancement of rare disease research.

Health & Medicine

17 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
07.13.2026

Join BioHarvest Sciences at the Health and Wellness Conference to Discover Innovations in Longevity Solutions

Update BioHarvest Sciences Embraces the Future of Health and Wellness In a significant move, BioHarvest Sciences Inc. (NASDAQ: BHST) is set to showcase its innovations at the Health, Wellness & Longevity virtual conference on July 22, 2026. This event is organized by Maxim Group LLC, a pivotal platform where leaders from various sectors in the health and wellness industry converge to discuss the latest trends, scientific advancements, and consumer preferences. Highlighting Innovative Technologies in Health The CEO of BioHarvest, Zaki Rakib, will lead a fireside chat at the conference. This format allows for an in-depth conversation about the current trends in health and wellness, particularly focusing on how innovative technologies like BioHarvest's patented Botanical Synthesis can shape the future of supplements and nutraceuticals. With a growing consumer base seeking sustainable and plant-based options, BioHarvest's pioneering solutions are poised to be at the forefront of this shift. The Role of Consumer Preferences Understanding shifting consumer preferences is crucial in the nutritional supplement market. As focus shifts toward natural and effective ingredients, industries are making strides toward transparency and efficacy in the products consumers choose. BioHarvest's place at this conference underscores its commitment to developing clinically proven solutions that cater to these evolving consumer demands. Market Trends and Future Predictions The conversation at the conference will likely touch upon current market trends, including the rising interest in holistic health and wellness solutions. According to recent studies, the global health and wellness market is projected to exceed $4 trillion by 2025, with plant-based wellness solutions carving out a substantial share of this segment. BioHarvest is strategically positioned to leverage this growth through its innovative technologies. Counterarguments and Diverse Perspectives on Innovation While BioHarvest champions the benefits of botanical synthesis, there are ongoing discussions about the regulation and safety of new supplements. Critics often emphasize the need for rigorous clinical trials and consistent product quality. This is a critical point that BioHarvest addresses, emphasizing their transparency and commitment to scientific validation through regulated clinical assessments. Unique Value of Attending the Conference This conference is not just an opportunity for BioHarvest to promote its products; it serves as a knowledge-sharing platform for industry stakeholders. Attendees will gain actionable insights from various discussions about navigating regulatory landscapes, consumer trust, and brand-building strategies in an increasingly competitive market. Engagement with Key Industry Players Maxim Group’s organizing of this virtual conference provides an excellent venue for networking, allowing companies to align their strategies with emerging trends and collaborate on sustainable innovations. The ability for industry leaders to engage directly with the audience creates a unique opportunity for sharing best practices and forging beneficial partnerships. The Future of Health and Longevity As BioHarvest prepares to share its vision at this influential gathering, industry experts believe that discussions around longevity will continue to gain momentum. With advancements in biotechnology, there are promising therapeutic solutions on the horizon that could revolutionize preventative health care and age-defying strategies. For anyone invested in the health and wellness space, the participation of BioHarvest Sciences in the upcoming conference could signal important developments that benefit various stakeholders, including consumers. It showcases a blend of science, consumer preferences, and innovative technologies converging for future solutions in a dynamic industry. Stay informed by following BioHarvest’s updates as they continue to break ground with their botanical synthesis technology and participate actively in industry dialogues.

07.13.2026

Trump's Greenland Purchase Push Revived: NATO, Resources, and Tensions Ahead

Update Trump's Bold Assertions at NATO Summit During a recently convened NATO summit in The Hague, President Donald Trump made waves by reviving his long-standing interest in acquiring Greenland. Citing critical geopolitical factors such as rare earth minerals and NATO tensions, Trump expressed a controversial stance that mirrors global power dynamics. Denmark's Firm Rejection Despite Trump's vocal assertions, Danish Prime Minister Mette Frederiksen firmly reiterated that Greenland is not for sale. She emphasized respect for the territory’s sovereignty and the right of its people to self-determination, reinforcing Denmark's commitment to maintaining control over the Arctic region. Rare Earth Minerals: A Driving Force Trump's comments shed light on the strategic importance of rare earth minerals—essential elements necessary for advanced technologies—underscoring their potential to enhance national security. With mounting competition from China, the U.S. is eager to secure these resources, adding urgency to Trump’s push for Greenland. The Specter of Military Action Unsettling many, Trump's previous comments hint at the possibility of military action to achieve this ambitious acquisition, further straining relationships within the NATO alliance. The specter of such strategies raises pivotal questions about international law and the ethics of territorial acquisition through force. Global Reactions and Future Implications The revival of Trump's Greenland proposal has implications beyond U.S.-Danish relations. It could reshape alliances and provoke responses from other nations with vested interests in the Arctic, including Russia and China, forcing a reconsideration of geopolitical strategies and alliances in the region. As Trump's administration continues to navigate complicated global tensions, maintaining a balance between national interests and diplomatic respect for other nations will be crucial. The international community will be watching closely as this narrative unfolds.

07.11.2026

RFK Jr. Aims to Create COVID Vaccine Injury Table: A New Era for Compensation?

Update Understanding the COVID Vaccine Injury Table Initiative Robert F. Kennedy Jr. (RFK Jr.) is spearheading an initiative to create a comprehensive COVID vaccine injury table. This database aims to provide a transparent overview of injuries linked to COVID vaccines, addressing a growing concern within both the medical community and affected individuals. By documenting these injuries, RFK Jr. seeks to ensure that people who suffer from vaccine-related side effects are acknowledged and potentially eligible for compensation. Addressing Vaccine Hesitancy and Concerns The move comes at a crucial time, as vaccine hesitancy has risen significantly, particularly among specific demographics. Many individuals have questions regarding vaccine safety, leading to a burgeoning demand for more information and accountability. By creating a clear delineation of vaccine injuries, Kennedy hopes to promote transparency in vaccine administration while potentially restoring confidence in vaccination as a public health measure. Implications for Compensation and Health Policies The creation of this injury table could also pave the way for clearer guidelines on compensation for vaccine injuries. Currently, individuals facing health issues after vaccination often struggle to receive recognition or compensation for their conditions. This initiative aims to streamline that process and provide a clearer path for those affected. Additionally, it may influence future health policies regarding vaccine development and distribution, potentially increasing scrutiny on manufacturers. What This Means for the Public For professionals, homemakers, and retirees concerned about health safety, this initiative might signal a turning point in public health dialogue. With more accurate data at their disposal, voters and community members can engage more meaningfully with policymakers. Such documentation could enhance informed decision-making among peers about vaccine choices amidst ongoing health discussions and campaigns. As we follow this initiative, it remains crucial for communities to stay informed on developments and foster an open dialogue surrounding vaccine safety and public health.

Where Conventional Meets Natural for a Healthier You

Parallel Health World News offers clarity and actionable knowledge for those eager to harmonize the best of both medical worlds, helping its audience achieve a truly integrative approach to health and wellness.

Advertise
Parallel Health World News
SeamanDan.com
Dan Seaman Media Press Pass

ABOUT US
SeamanDan LLC is a modern news media agency creating niche digital channels that inform and engage. We specialize in launching focused platforms that deliver impactful content.  Our current brands include:
Parallel Health World
AI Insights Hub
MLM News AI
Rider Safe News
Meme Crypto News
Rugged Trails Network
Recreation Wave
Outdoor Odyssey News
Eco-Innovation Hub
Metal Green Innovators
Autism Foundation News

At SeamanDan LLC, we don't just report the news we create platforms that build communities, foster trust, and drive forward-thinking conversations.  Can we build a channel for you?

© 2026 Parallel Health World News All Rights Reserved. 810 N Main St #187, Spearfish, SD 57783 . Contact Us . Terms of Service . Privacy Policy

{"company":"Parallel Health World News","address":", ,  ","city":"","state":"","zip":"","email":"seamandan@seamandan.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*